Triple-negative breast cancer (TNBC), which accounts for up to 20% of cases of breast cancer, is one of the most aggressive and difficult to treat subtypes of the disease.
Breast cancer was the second most frequent cause of new cancer cases worldwide in 2024, and up to 20% of cases fall under the subtype of triple-negative breast cancer (TNBC), one of the most aggressive and difficult subtypes to treat.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of triple-negative breast cancer.
Korea University Research & Business Foundation Sejong Campus has described thiobenzimidazole derivatives reported to be useful for the treatment of breast cancer.
A team at Baylor College of Medicine conducted research to identify novel cell-surface cancer/germline antigens (CGAs) expressed in triple-negative breast cancer (TNBC) that could serve as targets for development of CAR T therapies against this disease.
Triple-negative breast cancer (TNBC) is among the most aggressive breast cancer subtypes, with high metastasis and recurrence rates, as well as poor survival. While various molecular targets for TNBC do exist, the low proportion of expression of these molecules in TNBC tissues limits the number of patients that benefit from molecular therapeutics.
Inatherys SAS recently presented preclinical data for INA-03, an anti-transferrin receptor (TfR1/CD71) antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer (TNBC). INA-03 was constructed by conjugating an antimitotic payload (MMAE) to a humanized IgG4 anti-human CD71 antibody using a novel valine-citrulline linker.
Triple-negative breast cancer (TNBC) remains one of the most aggressive and challenging subtypes to treat due to the lack of targeted therapies. Therefore, identifying molecular drivers of TNBC progression and metastasis is crucial for the development of new treatment strategies.
Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer, lacking targeted therapies due to its molecular characteristics. Tumor-associated neutrophils (TANs), particularly the pro-tumor N2-type, contribute to TNBC progression and resistance to treatment.
One of the proteins required for centrosome clustering is kinesin family member C1 (KIFC1/HSET), and modulation of KIFC1 stability could reduce its activity in cancer cells.
